![]() |
The American Fibromyalgia Syndrome Association, Inc.
Financial ReportJuly 1, 2000 thru June 30, 2001 |
In less than a decade, AFSA has grown from a small grassroots research funding charity that began in 1993 to what is now the nation's sole organization focused on seeding investigators worldwide on FMS/CFS and pain related studies. For the past two years, AFSA-funded projects have dominated major scientific events on the syndrome (see our August 2001 Update publication for more details) and even more exciting is the fact that the groundbreaking findings by AFSA-funded research are also getting published in major medical journals. This is the arena most highly regarded as the source of valid information and education for practicing physicians and researchers alike. For example, Dr. Wallace's project on the role of cytokines appeared in the July issue of Rheumatology (click here for a brief overview of the published journal article). The first half of Dr. Jasmin's project, which evaluates the ability of substance P and noradrenaline to boost the effects of opioids to tame the painful symptoms of FMS/CFS, appeared in the January 2001 issue of the Proceedings of the National Academy of Science. The first portion of Dr. Marchand's project, comparing the ability of the Diffuse Noxious Inhibitory Control (DNIC) system to reduce pain in FMS patients, low back pain patients and healthy controls, just appeared in the March 2002 issue of PAIN.
Although AFSA's success in achieving its research funding mission is beginning to have a substantial impact on the way FMS is perceived by the research community, the dominating force behind AFSA has remained constant. The funds raised through AFSA are still derived almost exclusively from individual patient contributions. We did receive corporate sponsorship for the AFSA 2000 Seminar (see details below), but the heart of AFSA relies almost exclusively on donations from patients and their loved ones. During its eighth year, ending June 30, 2001, AFSA received $114,688 in public donations, sales, education seminar fees, and interest. This brings our cumulative revenue and support up to $927,864.
For the past three years we have received a total of nearly $380,000 with virtually no fundraising costs. In addition, we are an all-volunteer organization and our overhead office expenses are donated freely to us as in-kind services. What this means is that most of our contributions have come from previous donors and people receiving our organization's activity newsletter, the AFSA Update. This speaks volumes about the commitment of our patrons and it has helped ensure that a tremendously high percentage of the money donated to AFSA (over 94%) goes toward our program services (research grants and educational activities).
After the fiscal year ended, two additional research grants were awarded. The paperwork for the 21st project to Dr. Jasmin was in the works as the year came to a close and the 22nd project to Laurence Bradley, Ph.D., was made in January of 2002. The details of Jasmin's award are provided in the August 2001 Update, while Bradley's award was just mailed out in the January 2002 Update (and will soon be posted on the Web site as well). The point is, AFSA's financial reserves are the lowest that they have been in over three years. We have never awarded money to an unworthy project just because we had the money in the bank to do so with carryover funds from the previous year. We felt strongly that we would eventually receive those well-thought-out applications that we were yearning for ... which is exactly what happened with the funding of the last few projects! Now we are in a position where we need to rebuild our reserves, but our philosophy will remain the same: we will only fund project proposals that are of superior quality and highly patient-relevant.
| BALANCE SHEETS - June 30, 1994, 1995, 1996, 1997, 1998, 1999, 2000 and 2001 | |||||||||||
|
8th Year
|
7th Year
|
6th Year
|
5th Year
|
4th Year
|
3rd Year
|
2nd Year
|
1st Year
|
||||
|
00-01
|
99-00
|
98-99
|
97-98
|
96-97
|
95-96
|
94-95
|
93-94
|
||||
| ASSETS | |||||||||||
| CASH AND CASH EQUIVALENTS | |||||||||||
| Unrestricted |
114,139
|
134,671
|
124,855
|
136,268
|
67,712
|
10,136
|
4,431
|
11,483
|
|||
| Restricted |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|||
| Prepaid expenses - postage meter |
549
|
399
|
948
|
597
|
0
|
0
|
765
|
286
|
|||
| Inventory |
0
|
0
|
0
|
0
|
0
|
1,949
|
|||||
| TOTAL CASH |
114,688
|
135,070
|
125,803
|
136,865
|
67,712
|
12,085
|
5,196
|
11,769
|
|||
| TOTAL ASSETS |
114,688
|
135,070
|
125,803
|
136,865
|
67,712
|
12,085
|
5,196
|
11,769
|
|||
| LIABILITIES AND FUND BALANCES | |||||||||||
| TOTAL LIABILITIES |
0
|
0
|
0
|
0
|
0
|
0
|
23
|
0
|
|||
| FUND BALANCES | |||||||||||
| Unrestricted |
114,688
|
135,070
|
125,803
|
136,865
|
67,712
|
12,085
|
5,173
|
11,769
|
|||
| Restricted |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|||
| TOTAL FUND BALANCES |
114,688
|
135,070
|
125,803
|
136,865
|
67,712
|
12,085
|
5,173
|
11,769
|
|||
| TOTAL LIABILITIES AND FUND BALANCES |
114,688
|
135,070
|
125,803
|
136,865
|
67,712
|
12,085
|
5,196
|
11,769
|
|||
| STATEMENT OF REVENUE AND SUPPORT, EXPENSES AND CHANGES IN FUND BALANCES Year-end June 30, 2001 (with comparable totals for 2000, 1999, 1998, 1997, 1996, 1995, and 1994) | ||||||||||||
|
8th Year
|
7th Year
|
6th Year
|
5th Year
|
4th Year
|
3rd Year
|
2nd Year
|
1st Year
|
|||||
|
00-01
|
99-00
|
98-99
|
97-98
|
96-97
|
95-96
|
94-95
|
93-94
|
|||||
| REVENUE AND SUPPORT | ||||||||||||
| Contributions |
102,307
|
81,495
|
109,783
|
235,522
|
142,519
|
97,520
|
70,623
|
18,115
|
||||
| Note cards |
824
|
740
|
2,019
|
12,436
|
13,174
|
12,195
|
--
|
--
|
||||
| AFSA 2000 Seminar Fees |
13,370
|
--
|
--
|
--
|
--
|
--
|
--
|
--
|
||||
| AFSA 2000 Transcripts |
1,450
|
--
|
--
|
--
|
--
|
--
|
--
|
--
|
||||
| Abstracts & Calendars |
0
|
0
|
59
|
895
|
720
|
3,556
|
6,165
|
--
|
||||
| Interest and Other |
2,620
|
3,218
|
2,407
|
15
|
0
|
0
|
0
|
0
|
||||
| TOTAL REVENUE & SUPPORT |
120,571
|
85,453
|
114,268
|
248,868
|
156,413
|
113,271
|
76,788
|
18,115
|
||||
| EXPENSES | ||||||||||||
| PROGRAM SERVICES | ||||||||||||
|
Research
|
84,300
|
49,407
|
109,708
|
153,225
|
81,957
|
89,704
|
59,420
|
0
|
||||
|
Educational
Activities
|
|
|||||||||||
|
AFSA
Update
|
4,292
|
20,130
|
10,914
|
7,923
|
7,547
|
13,326
|
16,259
|
4,500
|
||||
|
AFSA
2000 Seminar
|
45,623
|
--
|
--
|
--
|
--
|
--
|
--
|
--
|
||||
| SUPPORT SERVICES | ||||||||||||
| Management and General |
7,506
|
6,263
|
4,659
|
5,598
|
4,490
|
1,671
|
3,029
|
872
|
||||
| Development |
20
|
385
|
0
|
12,969
|
6,788
|
1,662
|
4,676
|
974
|
||||
| TOTAL EXPENSES |
141,741
|
76,185
|
125,281
|
179,715
|
100,782
|
106,363
|
83,384
|
6,346
|
||||
| EXCESS (DEFICIENCY) OF SUPPORT AND REVENUE OVER EXPENSES |
(27,053)
|
9,268
|
(11,012)
|
69,153
|
55,631
|
6,908
|
(6,596)
|
11,769
|
||||
| FUND BALANCES | ||||||||||||
| Beginning of Year |
135,120
|
125,852
|
136,865
|
67,712
|
12,081
|
5,173
|
11,769
|
0
|
||||
| End of Year |
108,067
|
135,120
|
125,852
|
136,865
|
67,712
|
12,081
|
5,173
|
11,769
|
||||
Six hundred and fifty-eight people donated $77,119 to AFSA during the fiscal year. Of this, $16,000 was in the form of unrestricted educational grants received to help fund the AFSA 2000 conference. The average donation was $117 per person, not up substantially from the $110 per person we received last year. From the pie-chart below, it is clear that we have more donors contributing larger amounts. Twenty-eight percent of our support came from contributions over $1000. Fifteen percent came from contributions between $100 and $500. Memorials and honorariums accounted for eleven percent of our support, while the AFSA 2000 conference contributed another twelve percent.

Development costs are those expenses associated with raising funds for AFSA. The printing and mailing costs for any fund raiser fall into this category. For the past three years, AFSA has not had an annual fund raiser. AFSA had funds to carry-over from previous years that we have now been successful in allocating to research.
Management costs, the costs associated with running the organization, were up from previous years by roughly $1200. Most of this was due to the extra expense associated with office supplies consumed by the AFSA 2000 conference ($500) and accounting fees ($600).
Educational costs include the printing and postage for sending out the organization's newsletter, the AFSA Update, and the cost of sending out information about fibromyalgia. They also include most of the costs associated with holding the AFSA 2000 conference. Because of the large cost of the conference, its expenses are broken out from other educational expenses in the pie-chart below. A more detailed break out of AFSA 2000 conference revenue and expenses are provided in the table below.
|
AFSA produced one issue of the AFSA Update during its eighth year; in October 2000. Articles from this issue are available online by clicking on the button entitled, "Updates." You can also request copies of these newsletters from AFSA by calling (520) 733-1570. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Our initial goals for the AFSA 2000 seminar were to educate health care providers while taking advantage of the large assembly of researchers to discuss future directions in AFSA's research funding mission. We sent flyers and registration materials to over 6,000 (and posted the information on our Web site as well), but we received little enthusiasm from the health care community. One month before the event, we switched gears and converted the seminar into a one-day patient education seminar with a second-day roundtable discussion that greatly enhanced AFSA and defined our research funding goals. Clearly, patients are eager to do whatever it takes to learn about their illness and the success of the event can be attributed to their enthusiasm.
The objectives of the seminar that took place on August 7th and 8th were twofold. One was to educate patients. We had close to 200 attendees and we have sent the seminar transcripts to 29 people (mostly health care providers) to help educate them about this condition. The second focus of the seminar was to gather together a group of 30 researchers (including several advisors to AFSA) to pin down research priorities and to develop grant review procedures that place a greater emphasis on patient relevance. In other words, a project proposal could be technically exciting, but offer little or no hope of helping patients in the foreseeable future. Based on the four-hour roundtable discussion with the researchers on the day following the patient seminar, these issues were addressed and solutions were developed. AFSA is now implementing a new application grading procedure that places a heavy focus on patient needs. Not only must projects be budget conscious and scientifically intriguing, they must also score high marks on the perceived ability of the project to favorably impact the lives of patients. Prior to the seminar, grant reviewers were asked to take into strong consideration the patient-relevance of a given proposal, but now we have an official grading system that places patient-relevance as the number one priority.
Other stumbling blocks in the grant review procedures were smoothed over during the second-day discussion to help standardize the grading process. In addition, it was agreed upon that while single-therapy treatment trials were often performed for testing the effectiveness for most medical conditions, this concept did not work for FMS/CFS. No single therapy was likely to work for the majority of patients with FMS/CFS, so it was concluded that the testing of new therapies needed to be designed as add-on treatments. It was also deemed to be more ethical because asking a person with FMS/CFS to go off of all of their therapies for three to six months was too harsh on participants and singleton therapies are not likely to show promising results for most patients.
AFSA is proud to have funded two superb studies. The first, "Autoimmune Mechanisms of Disordered Pain Perception," went to molecular biologist Thomas Fasy, M.D., Ph.D., of Mount Sinai School of Medicine. The second, "Opioid Receptors in the Skin and Muscle Tissue of FMS Patients - Part 2" was awarded to Haiko Sprott, M.D., of Zurich, Switzerland. Details can be read online by clicking on the button entitled, "Research Projects Funded."
AFSA has made tremendous progress! Yet today, AFSA's reserves are the lowest that they have been in more than three years. After we closed out the year, we funded two additional projects totaling $84,974. Two AFSA Updates were also published in August 2001 and January 2002, but they generated much lower revenues than in years past.
Note 1 - Accounting Policies
Description of operations
The American FMS Association, Inc. (AFSA) is a non-profit corporation whose primary mission is to encourage scientific research toward finding the cause of and cure for fibromyalgia syndrome and chronic fatigue syndrome, as well as to promote public awareness and understanding of these conditions. AFSA accomplishes this mission by funding exceptional research that is focused on the physiology and treatment of these illnesses. It also educates the public through dissemination of free information packets and newsletters. The majority of AFSA's revenue is derived from contributions from the public and from the sale of informational items.
Inventories
Inventories, which consist of informational note cards and AFSA 2000 syllabuses, are recorded at cost on a first-in, first-out basis.
Donated services
AFSA receives donated services for certain functions. However, there is no objective basis for measuring the value of donated services. Therefore, no amounts have been included in the accompanying financial statements for these services.
Revenue recognition
Contributors, though often called members, do not receive any goods or services for their contributions that are not available to the general public at no charge. Therefore, AFSA recognizes all contributions as revenues when received, except for pledges. Pledges are recognized as revenue at the time that monies associated with the pledge are received. Contributions and sales are considered to be available for unrestricted use unless specified by the contributor.
Research grants
AFSA's primary goal is to fund medical research projects on fibromylagia syndrome, chronic fatigue syndrome, and related areas. Each year, AFSA attempts to maximize the amount it awards in grants of this type. To ensure that the most worthy and promising research projects are funded, AFSA utilizes a Medical Advisory Committee (MAC) to review and grade grant applications received by AFSA. The MAC is comprised of many of the most noted researchers in the area of fibromylagia and chronic fatigue syndrome research. In addition to the MAC, AFSA enlists the advice of other experts in the field on an as-needed, voluntary basis. Grades received from the MAC are the primary tool used by the Executive Committee in deciding which projects should be funded. However, the Executive Committee is ultimately responsible for making all funding decisions.
Conflict of interest
All members of AFSA's Board of Directors and Medical Advisory Committee are governed by a conflict-of-interest policy. This policy precludes members from voting on motions with respect to which he/she may have a conflict of interest. Conflict of interest is deemed to exist if the member would directly benefit, personally or professionally, from a motion that has been made.
Note 2 - Tax Status
AFSA is a not-for-profit voluntary health organization, exempt from federal and state income tax under Section 501(c)(3) of the Internal Revenue Code and Sections 23701d of the General Statutes of California. AFSA's advanced ruling period under Federal law ended June 30, 1998. AFSA has now received its final approval as a publicly supported organization described in sections 170(b)(1)(A)(1) or in section 509(a)(2) of the Internal Revenue Code.
AFSA, Inc., 6380 E.
Tanque Verde, Suite D, Tucson, AZ 85715
(520) 733-1570
Copyright © 2000 - American Fibromyalgia Syndrome Association, Inc.